Armada Health Care achieves full URAC accreditation
FLORHAM PARK, N.J. — Armada Health Care, a specialty pharmacy channel management organization, announced that the organization has been awarded Health Call Center, Health Web Site and Health Content Provider accreditation from URAC, a Washington, D.C.-based healthcare accrediting organization that establishes quality standards for the healthcare industry.
"Armada continues to expand its portfolio of specialty solutions and patient services for our member pharmacy network and pharmaceutical manufacturer partners," stated Armada CEO, Lawrence Irene , R.Ph. "We have a commitment to quality and see URAC Accreditation as a critical step in continuing to provide a high-quality, patient-centric approach as we both expand existing services and develop new programs for these important industry partners."
"We applaud Armada on achieving URAC Health Call Center, Health Web Site and Health Content Provider accreditation," said Alan P. Spielman, URAC president and CEO. "In today’s healthcare market, URAC accreditation provides a mark of distinction for organizations to demonstrate their commitment to quality health care."
URAC Health Call Center standards apply to organizations providing triage and health information services to the public when conducted by telephone, via website or other electronic means. The standards assure that registered nurses, physicians or other validly licensed individuals perform the clinical aspects of triage and other health information services in a manner that is timely, confidential, and includes medically appropriate care and treatment advice.
The URAC Health Web Site Accreditation program is an innovative, cost-effective quality improvement service that provides meaningful feedback to health website owners on how to improve the quality of online operations, including:
- Privacy and security;
- Health content editorial processes;
- Disclosure of financial relationships;
- Linking policies;
- Consumer complaints; and
- Emerging best practices.
The URAC Health Content Provider Accreditation program requires health content providers to develop editorial policies and apply these policies to health content licensed to other websites.
Sephora launches YOU+Sephora cosmetics collection to benefit charities
SAN FRANCISCO — Following the launch of Values Inside Out, Sephora’s charitable platform has presented the first limited-edition cosmetic collection to benefit its nonprofit partners.
The YOU + SEPHORA cosmetic collection, which will be available June 1 in all U.S. Sephora stores and on Sephora.com, retails for $20 and features a covetable clutch, glitter eye liner, lip gloss and nail polish. Sephora USA Inc. will donate $13 for each bag sold in-store to the store’s selected charity, while bags sold on Sephora.com will benefit the American Heart Association.
YOU + SEPHORA features:
- One collectable cosmetic pouch perfect for purse, travel or gym bag;
- One mini lip gloss in a dusty pink shimmer finish that you can apply over your favorite lipstick or wear alone;
- One mini gold glitter liquid eyeliner that you can wear alone or layer to brighten the glitter effect; and
- One mini nail polish in a warm champagne metallic finish to act as the finishing touch for your summer ensembles.
"At Sephora, our continual mission for Values Inside Out is to inspire and engage our teams to play a part in making a difference in their communities, and this bag allows them to do just that, share their passion for cosmetics with their clients that ultimately supports our charitable partners across the country," stated Mary Herald, Sephora’s EVP of human resources and education.
Valeant to buy Bausch & Lomb
ROCHESTER, N.Y. — Canadian drug maker Valeant Pharmaceuticals International is buying U.S.-based Bausch & Lomb Holdings for $8.7 billion, the companies said Monday.
Bausch & Lomb makes prescription and over-the-counter eye health products, as well as contact lenses and solutions and eye-surgery equipment.
"Bausch & Lomb’s world-renowned brand, comprehensive portfolio of leading eye-care products and promising late-stage pipeline are an ideal strategic fit for our current ophthalmology business, and we are strongly committed to continuing to build a sustainable eye-health business," Valeant chairman and CEO J. Michael Pearson said. "With this transaction, Valeant will be a worldwide leader in both dermatology and eye health."
Valeant’s all-cash offer for the company includes $4.5 billion to an investor group led by Warburg Pincus and $4.2 billion to pay Bausch & Lomb’s outstanding debt.
In other news, the Food and Drug Administration declined to approve an experimental drug made by Valeant for the fungal nail infection onychomycosis. The drug maker announced Tuesday that it received a complete-response letter from the FDA for efinaconazole, meaning that the agency had finished reviewing its application for the drug, but questions about its chemistry, manufacturing and controls remained that precluded approval.